Skip to content

Multimodal Omics Analysis of Exhaled Breath Condensate and Its Application in Lung Cancer Diagnosis: A Prospective, Multicenter Study

Multimodal Omics Analysis of Exhaled Breath Condensate and Its Application in Lung Cancer Diagnosis: A Prospective, Multicenter Study

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600120245
Enrollment
Unknown
Registered
2026-03-11
Start date
2026-03-21
Completion date
Unknown
Last updated
2026-03-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung cancer

Interventions

Gold Standard:Diagnosis of lung cancer: Histopathological examination after tumor puncture or surgical resection confirms lung cancer.
Index test:Single-omics analysis and multi-omics integrated analysis of exhaled breath condensate, including genomic, transcriptomic, proteomic, metabolomic, and microbiomic analyses.

Sponsors

The First Affiliated Hospital of Zhengzhou University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Inclusion Criteria for Lung Cancer Patients: 1. Age > 18 years; 2. Diagnosed with lung cancer or suspected lung cancer scheduled for surgical resection; 3. No prior history of malignant tumors; 4. No prior anti-tumor treatments such as radiotherapy, chemotherapy, or targeted therapy. Inclusion Criteria for Healthy Subjects: 1. Age > 18 years; 2. No space-occupying lesions found on chest CT; 3. No current or prior history of malignant tumors.

Exclusion criteria

Exclusion criteria: Exclusion Criteria for Lung Cancer Patients: 1. Inability to tolerate the collection procedure of exhaled breath condensate; 2. Presence or suspicion of active infection; 3. Abnormal liver or kidney function; 4. Postoperative pathology negates the diagnosis of lung cancer; 5. Insufficient volume of exhaled breath condensate collected or failure to pass quality inspection. Exclusion Criteria for Healthy Subjects: 1. Inability to tolerate the collection procedure of exhaled breath condensate; 2. Presence or suspicion of active infection; 3. Abnormal liver or kidney function; 4. Insufficient volume of exhaled breath condensate collected or failure to pass quality inspection.

Design outcomes

Primary

MeasureTime frame
Sensitivity;specificity;

Secondary

MeasureTime frame
Multi omics abnormalities related to lung cancer;

Countries

China

Contacts

Public ContactLi Xiangnan

The First Affiliated Hospital of Zhengzhou University

lxn-2000@163.com+86 135 9250 2553

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Mar 20, 2026